Compare United Microelectronics Corp (UMC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? United Microelectronics Corp trades at $23.13 (market cap $58.54B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× United Microelectronics Corp's market cap, and United Microelectronics Corp pays a 1.72% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold United Microelectronics Corp for 42 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UMC | VRTX | |
|---|---|---|
Market Cap | $58.54B | $128.16B |
Volume | 8,050,715 | 806,603 |
Sector | Technology | Health |
52-Week High | $28.02 | $557.96 |
52-Week Low | $7.02 | $407.37 |
Typical Hold Time | 42 Days | 120 Days |
Enterprise Value | $55.62B | $122.29B |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $22.82, down 1.6% on the day, with a bullish technical signal despite mixed moving average indicators. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue growth remains steady, projected to reach $250.7B in 2026, while net income margin is expected to rebound to 32.75%. Recent news highlights strong AI-driven demand and specialty chip expansion.
UMC presents a mixed investment case with strong earnings momentum and AI growth potential offset by declining profit margins and competitive pressures. The stock appears moderately valued with a P/E of 22.48, while analyst consensus leans Hold (53.33%) with some institutional selling activity. Key risks include semiconductor cycle volatility and AI spending concerns impacting foundry stocks.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
